OMEROS CORP Finance Lease, Right-of-Use Asset, Amortization
OMEROS CORP (OMER) reported Finance Lease, Right-of-Use Asset, Amortization of $142.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-08-12
- OMEROS CORP finance lease, right-of-use asset, amortization for the quarter ending 2026-06-30 was $142.00K, a 39.32% decline year-over-year.
- OMEROS CORP finance lease, right-of-use asset, amortization for the quarter ending 2026-03-31 was $186.00K, a 20.51% decline year-over-year.
- OMEROS CORP finance lease, right-of-use asset, amortization for the quarter ending 2025-12-31 was $185.00K, a 22.92% decline year-over-year.
- OMEROS CORP finance lease, right-of-use asset, amortization for the quarter ending 2025-09-30 was $186.00K, a 7.51% increase year-over-year.
- OMEROS CORP finance lease, right-of-use asset, amortization for fiscal 2025 was $738.00K, a 4.24% increase from fiscal 2024.
- OMEROS CORP finance lease, right-of-use asset, amortization for fiscal 2024 was $708.00K, a 4.58% increase from fiscal 2023.
- OMEROS CORP finance lease, right-of-use asset, amortization for fiscal 2023 was $677.00K, a 16.63% decline from fiscal 2022.
- OMEROS CORP finance lease, right-of-use asset, amortization for fiscal 2022 was $812.00K, a 26.32% decline from fiscal 2021.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2026-06-30 | $142.00K 10-Q · filed 2026-08-12 | $328.00K 10-Q · filed 2026-08-12 | $513.00K derived: sum of 3 quarters · filed 2026-08-12 | $699.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $186.00K 10-Q · filed 2026-05-13 | $371.00K derived: sum of 2 quarters · filed 2026-05-13 | $557.00K derived: sum of 3 quarters · filed 2026-05-13 | $791.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $185.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $371.00K derived: sum of 2 quarters · filed 2026-03-31 | $605.00K derived: sum of 3 quarters · filed 2026-08-12 | $738.00K 10-K · filed 2026-03-31 |
| 2025-09-30 | $186.00K 10-Q · filed 2025-11-13 | $420.00K derived: sum of 2 quarters · filed 2026-08-12 | $553.00K 10-Q · filed 2025-11-13 | $894.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $234.00K 10-Q · filed 2026-08-12 | $367.00K 10-Q · filed 2026-08-12 | $708.00K derived: sum of 3 quarters · filed 2026-08-12 | $881.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $234.00K 10-Q · filed 2026-05-13 | $474.00K derived: sum of 2 quarters · filed 2026-05-13 | $647.00K derived: sum of 3 quarters · filed 2026-05-13 | $796.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $240.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $413.00K derived: sum of 2 quarters · filed 2026-03-31 | $562.00K derived: sum of 3 quarters · filed 2026-03-31 | $708.00K 10-K · filed 2026-03-31 |
| 2024-09-30 | $173.00K 10-Q · filed 2025-11-13 | $322.00K derived: sum of 2 quarters · filed 2025-11-13 | $468.00K 10-Q · filed 2025-11-13 | $615.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $149.00K 10-Q · filed 2025-08-14 | $295.00K 10-Q · filed 2025-08-14 | $442.00K derived: sum of 3 quarters · filed 2025-08-14 | $582.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $145.00K 10-Q · filed 2025-05-15 | $293.00K derived: sum of 2 quarters · filed 2025-05-15 | $433.00K derived: sum of 3 quarters · filed 2025-05-15 | $704.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $148.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $288.00K derived: sum of 2 quarters · filed 2025-03-31 | $559.00K derived: sum of 3 quarters · filed 2025-03-31 | $677.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $140.00K 10-Q · filed 2024-11-13 | $411.00K derived: sum of 2 quarters · filed 2024-11-13 | $529.00K 10-Q · filed 2024-11-13 | $771.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $271.00K 10-Q · filed 2024-08-07 | $389.00K 10-Q · filed 2024-08-07 | $631.00K derived: sum of 3 quarters · filed 2024-08-07 | $881.00K derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $118.00K 10-Q · filed 2024-05-15 | $360.00K derived: sum of 2 quarters · filed 2024-05-15 | $610.00K derived: sum of 3 quarters · filed 2024-05-15 | $732.00K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $242.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $492.00K derived: sum of 2 quarters · filed 2024-04-01 | $614.00K derived: sum of 3 quarters · filed 2024-04-01 | $812.00K 10-K · filed 2024-04-01 |
| 2022-09-30 | $250.00K 10-Q · filed 2023-11-09 | $372.00K derived: sum of 2 quarters · filed 2023-11-09 | $570.00K 10-Q · filed 2023-11-09 | $817.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $122.00K 10-Q · filed 2023-08-09 | $320.00K 10-Q · filed 2023-08-09 | $567.00K derived: sum of 3 quarters · filed 2023-08-09 | $810.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $197.00K 10-Q · filed 2023-05-09 | $445.00K derived: sum of 2 quarters · filed 2023-05-09 | $688.00K derived: sum of 3 quarters · filed 2023-05-09 | $976.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $248.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | $491.00K derived: sum of 2 quarters · filed 2023-03-13 | $779.00K derived: sum of 3 quarters · filed 2023-03-13 | $1.10M 10-K · filed 2023-03-13 |
| 2021-09-30 | $243.00K 10-Q · filed 2022-11-09 | $531.00K derived: sum of 2 quarters · filed 2022-11-09 | $854.00K 10-Q · filed 2022-11-09 | $1.18M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $288.00K 10-Q · filed 2022-08-09 | $611.00K 10-Q · filed 2022-08-09 | $939.00K derived: sum of 3 quarters · filed 2022-08-09 | $1.27M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $323.00K 10-Q · filed 2022-05-10 | $651.00K derived: sum of 2 quarters · filed 2022-05-10 | $987.00K derived: sum of 3 quarters · filed 2022-05-10 | $1.33M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $328.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $664.00K derived: sum of 2 quarters · filed 2022-03-01 | $1.01M derived: sum of 3 quarters · filed 2022-03-01 | $1.37M 10-K · filed 2022-03-01 |
| 2020-09-30 | $336.00K 10-Q · filed 2021-11-09 | $681.00K derived: sum of 2 quarters · filed 2021-11-09 | $1.04M 10-Q · filed 2021-11-09 | $1.39M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $345.00K 10-Q · filed 2021-08-09 | $703.00K 10-Q · filed 2021-08-09 | $1.06M derived: sum of 3 quarters · filed 2021-08-09 | $1.40M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $357.00K 10-Q · filed 2021-05-10 | $713.00K derived: sum of 2 quarters · filed 2021-05-10 | $1.05M derived: sum of 3 quarters · filed 2021-05-10 | $1.41M derived: sum of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | $356.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $694.00K derived: sum of 2 quarters · filed 2021-03-01 | $1.05M derived: sum of 3 quarters · filed 2021-03-01 | $1.34M 10-K · filed 2021-03-01 |
| 2019-09-30 | $338.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $694.00K derived: sum of 2 quarters · filed 2020-11-09 | $984.00K 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $356.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $646.00K 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $290.00K 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |